Prevention of Tuberculosis in Patients Taking Tumor Necrosis Factor-α Blockers

被引：0

作者：

Bellofiore, Barbara ^{[1
]}

Matarese, Alessandro ^{[1
]}

Balato, Nicola ^{[2
]}

Gaudiello, Francesca ^{[2
]}

Scarpa, Raffaele ^{[3
]}

Atteno, Mariangela ^{[3
]}

Bocchino, Marialuisa ^{[1
]}

Sanduzzi, Alessandro ^{[1
]}

机构：

[1] Univ Naples Federico 2, Div Resp Dis, I-80131 Naples, Italy

[2] Univ Naples Federico 2, Div Dermatol, I-80131 Naples, Italy

[3] Univ Naples Federico 2, Div Rheumatol, I-80131 Naples, Italy

来源：

JOURNAL OF RHEUMATOLOGY | 2009年 / 36卷

关键词：

TUBERCULOSIS; TUMOR NECROSIS FACTOR-alpha BLOCKER; INTERFERON-gamma RELEASE ASSAYS; SKIN-TEST; T-CELLS; INFECTION; THERAPY; ENUMERATION; CANDIDATES; INFLIXIMAB; AGENTS; ASSAYS;

D O I：

10.3899/jrhewn.090233

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment with tumor necrosis factor-alpha (TNF-alpha) inhibitors increases the risk of tuberculosis (TB) due to reactivation of latent Mycobacterium tuberculosis infection (LTBI). Screening for LTBI is based mainly on the tuberculin skin test (TST), which has several limitations in any patient who is immunosuppressed due to drugs or autoimmune disease. T cell interferon-gamma release assays (IGRA) have been shown to be more specific than TST in immunocompetent patients and potentially represent a new approach for the management of patients taking TNF-alpha blockers. Even if there is no evidence-based literature of IGRA superiority versus TST in this specific clinical setting, some studies suggest blood assays may be helpful in clinical management of these patients, in addition to currently recommended clinical screening for risk factors for LTBI. (J Rheumatol 2009;36 Suppl 83:76-77; doi:10.3899/jrheum.090233)

引用

页码：76 / 77

页数：2

共 50 条

[1] The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
Byun, Ja Min
Lee, Chang Kyun
Rhee, Sang Youl
Kim, Hyo-Jong
Kim, Jung-Wook
Shim, Jae-Jun
Jang, Jae Young
[J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (02) : 173 - 179
[2] Screening and Monitoring of Latent Tubercular Infection in Patients Taking Tumor Necrosis Factor-α Blockers for Psoriatic Arthritis
Sanduzzi, Alessandro
Bocchino, Marialuisa
Atteno, Mariangela
Costa, Luisa
Ponticiello, Antonio
Matarese, Alessandro
Spano, Angelo
Bruner, Vincenzo
Peluso, Rosario
Aquino, Maria Maddalena
Del Puente, Antonio
Scarpa, Raffaele
[J]. JOURNAL OF RHEUMATOLOGY, 2012, 39 : 82 - 85
[3] Incidence of Tuberculosis Among Korean Patients with Ankylosing Spondylitis Who Are Taking Tumor Necrosis Factor Blockers
Kim, Eun-Mi
Uhm, Wan-Sik
Bae, Sang-Cheol
Yoo, Dae-Hyun
Kim, Tae-Hwan
[J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (10) : 2218 - 2223
[4] Tumor Necrosis Factor-α Blockers in SAPHO Syndrome
Ben Abdelghani, Kaouther
Dran, Delphine Gerard
Gottenberg, Jacques-Eric
Morel, Jacques
Sibila, Jean
Combe, Bernard
[J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (08) : 1699 - 1704
[5] Neuropathy resembling CIDP in patients receiving tumor necrosis factor-α blockers
Richez, C
Blanco, P
Lagueny, A
Schaeverbeke, T
Dehais, J
[J]. NEUROLOGY, 2005, 64 (08) : 1468 - 1470
[6] Mycobacterial Disease Attributable to Tumor Necrosis Factor-α Blockers
Wallis, Robert. S.
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (12) : 1603 - 1605
[7] Sarcoidosis As Paradoxical Effect Of Tumor Necrosis Factor-α Blockers
Patibandla, B. K.
Moulton, B. C.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[8] Tumor necrosis factor blockers and reactivation of latent tuberculosis
Keane, J
[J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) : 300 - 302
[9] Tumor Necrosis Factor-α Blocker Induced Tuberculosis
Kharbanda, Priyanka
Dagaonkar, Rucha
Balakrishnan, Canchi
Udwadia, Zarir F.
[J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (07) : 1542 - 1543
[10] Mycobacterial Disease Attributable to Tumor Necrosis Factor-α Blockers Reply
Iseman, Michael D.
Fischer, Aryeh
[J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (12) : 1605 - 1605

← 1 2 3 4 5 →